sub:assertion {
  d:DB00399 v:identifier "DB00399" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB00399" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB00399> ;
    dv:drugbank-id "APRD01294" , "DB00399" , "DB06286" ;
    dv:x-ahfs <http://bio2rdf.org/ahfs:92:00.00> ;
    dv:x-atc <http://bio2rdf.org/atc:M05BA08> ;
    dv:x-bindingdb <http://bio2rdf.org/bindingdb:12578> ;
    dv:x-cas <http://bio2rdf.org/cas:118072-93-8> ;
    dv:x-chemspider <http://bio2rdf.org/chemspider:61986> ;
    dv:x-dpd <http://bio2rdf.org/dpd:2242725> ;
    dv:x-kegg <http://bio2rdf.org/kegg:D01968> ;
    dv:x-ndc <http://bio2rdf.org/ndc:0078-0387-25> ;
    dv:x-pdb <http://bio2rdf.org/pdb:ZOL> ;
    dv:x-pharmgkb <http://bio2rdf.org/pharmgkb:PA10235> ;
    dv:x-pubchemcompound <http://bio2rdf.org/pubchem.compound:68740> ;
    dv:x-pubchemsubstance <http://bio2rdf.org/pubchem.substance:46507310> ;
    dv:x-wikipedia <http://bio2rdf.org/wikipedia:Zoledronate> ;
    dct:description """Zoledronate (zoledronic acid, marketed by Novartis under the trade names Zometa and Reclast) is a bisphosphonate. Zometa is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer. It can also be used to treat hypercalcemia of malignancy and can be helpful for treating pain from bone metastases.

An annual dose of Zoledronate may also prevent recurring fractures in patients with a previous hip fracture.

Zoledronate is a single 5 mg infusion for the treatment of Paget's disease of bone. In 2007, the FDA also approved Reclast for the treatment of postmenopausal osteoporosis."""@en ;
    dct:identifier "drugbank:DB00399" ;
    dct:title "Zoledronate"@en ;
    a dv:Drug ;
    rdfs:label "Zoledronate [drugbank:DB00399]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB00399> , <http://www.rxlist.com/cgi/generic/zometa.htm> .
}